Skip to NavigationSkip to content

Eli Lilly's Emgality shows positive Phase 3 results in treatment of migraine

Published on 08/05/19 at 11:06am

Eli Lilly has announced positive results from the Phase 3 EVOLVE-1 and EVOLVE-2 trials looking into Emgality (galcanezumab-gnlm) for the treatment of episodic migraine.

The drug was found to reduce the number of migraine headache days patients experienced each month, in comparison to placebo.

Patients – who were categorised as either low-frequency (four to seven migraine days a month) or high-frequency (eight to 14 monthly migraine days a month) – were given either 120mg or 240mg doses of Lilly’s Emgality.

Both doses were found to reduce the number of migraine days in both the low-frequency and high-frequency subgroups in comparison to placebo.

Lilly Bio-Medicines Neurology Development vice-president Gudarz Davar commented: “Migraine causes people to suffer from substantial pain and impairment, no matter how frequently they occur.”

“These collective analyses of more than 1,700 patients with episodic migraine from our Phase 3 Emgality programme reflect our continued commitment to aid people living with this serious neurologic disorder.”  

The FDA is also currently reviewing the monoclonal antibody, which specifically targets calcitonin gene-related peptide (CGRP), as a preventative treatment of episodic cluster headache in adults.

Louis Goss

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches